Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Instituto do Cancer do Estado de São Paulo
Stanford University
Second Affiliated Hospital, School of Medicine, Zhejiang University
Bayer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Washington University School of Medicine
Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas
Medical University of South Carolina
Second Affiliated Hospital, School of Medicine, Zhejiang University
National Institutes of Health Clinical Center (CC)
Italian Sarcoma Group
University Health Network, Toronto
QBiotics Group Limited
City of Hope Medical Center
Wake Forest University Health Sciences
University Health Network, Toronto
University of California, Irvine
M.D. Anderson Cancer Center
University of Pittsburgh
Hackensack Meridian Health
University of Colorado, Denver
Memorial Sloan Kettering Cancer Center
University of Wisconsin, Madison
Oslo University Hospital
Oslo University Hospital
Shanghai 6th People's Hospital
Fudan University
Swiss Cancer Institute
Sarcoma Alliance for Research through Collaboration
UNICANCER
Memorial Sloan Kettering Cancer Center
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
UNICANCER
M.D. Anderson Cancer Center
Institut Bergonié
Institut Bergonié
Ohio State University Comprehensive Cancer Center
British Columbia Cancer Agency
Institut Claudius Regaud
University Health Network, Toronto
Fudan University
Oslo University Hospital
Institut Bergonié
Nationwide Children's Hospital
HRYZ Biotech Co.
Medical College of Wisconsin
Yonsei University
University of Pittsburgh
University of California, Irvine